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Among the many things I learned at the American 
College of Rheumatology (ACR) meeting in Chicago this 
year is the answer to the question, ‘Which medical 
advance was developed in Chicago?’ Th  is nugget of 
information was not the product of a lecture or poster 
session. Rather, it was ﬂ  ashed on the computer screen in 
the shuttle bus that transported me every day from the 
Palmer House on Monroe Street to the McCormick Place 
convention center. Th  e convention center is gargantuan 
and is clearly vying for designation as one of the wonders 
of the modern world. Alas, the territory near the center is 
barren and only a Hyatt Regent hotel sits forlornly at the 
site, anxiously awaiting some company from brethren 
named Sheraton, Hilton or Ritz-Carlton.
Each day, the shuttle bus brought people from the 
downtown hotels from around the Loop and Gold Coast, 
through obstacles that included the snarl of traﬃ   c, cur-
tains of driving rain, and a road race in which seemingly 
every inhabitant of the state of Illinois put on his Nike 
shoes to run for the glory. To keep bus passengers 
bemused and serene during these sometimes tedious 
commutes, a computer system thoughtfully presented a 
series of questions about Chicago as divertissements and 
a few seconds later ﬂ  ashed the answers. Th   e only medical 
question concerned the advance hatched in the conﬁ  nes 
of the Windy City. Th   e choices were stethoscope, X-rays, 
kidney transplants and blood bank.
Th   e correct answer is blood bank.
Before my trip, I was totally unaware of this fact and 
was glad to learn it along with the ﬁ  rst animal purchased 
for the Chicago zoo, the name of the cookie factory 
located in the city and the amusement park attraction 
that debuted on the banks of Lake Michigan. Th  is 
information is permanently instilled in the memory 
banks of my brain since I had about a dozen round trips 
to the convention center and the questions and answers 
were repeated non-stop. Alas, this knowledge will not 
change my practice and I did not detect any commercial 
bias beyond some boosterism on the part of the city 
fathers and mothers to tout the history of a city the 
American poet Carl Sandburg called stormy, husky and 
brawling, not exactly attributes of most rheumatologists.
Once oﬀ   the bus at the convention center, the oppor-
tunity for real knowledge was staggering given the cornu-
copia of symposia, lectures and poster presentations. In a 
room that seemed bigger than the stockyards that made 
Chicago the hog butcher of the world, hundreds of bright 
eyed and bushy-tailed young investigators stood 
expectantly by their posters, eager to tell the story of 
their travails in the lab or in a data bank. Who knew there 
was so much new research? In contrast to the ACR meet-
ings of the past that were communal aﬀ  airs held in a 
single hotel, today’s meeting can convene in the very few 
cities that have enough hotel rooms for the thousands of 
attendees. Nevertheless, despite the throngs of people, 
today’s meetings are very impersonal, even isolating, as 
attendees race, charge and bound from room to room, 
diligently following a schedule that they have designed to 
get their own unique smattering of CME (Continuing 
Medical Education) goodies.
Since I am a researcher who spends his time doing 
science and reviewing for journals like Arthritis Research 
& Th  erapy, I use the ACR meeting to get updates on 
clinical subjects, especially unusual conditions I have 
seen on our consult service. Rheumatology is a strange 
subspecialty since, within its purview, are a large 
collection of virtually unrelated conditions that, for some 
arcane reasons, have been designated as ‘rheumatological’ 
and hence require subspecialty expertise. Th  e diﬃ   culty 
with this situation, of course, is that many of these 
conditions are quite rare and defy the acquisition of 
expertise. Nevertheless, the good rheumatologist, when 
asked to see a mysterious case that has eluded or 
befuddled other specialists, has to be ready to opine on 
amyloidosis, X-linked hypophosphatemic rickets or 
McArdle’s syndrome.
Th   us, this year, I went to lectures on hereditary angio-
edema, pyoderma gangrenosum and hypereosinophilic 
syndrome. Among things I learned was to think W when 
confronted with a patient with too many eos. Th  e W 
refers to worms, wheezes and weirdness. Th  e  weirdness  © 2010 BioMed Central Ltd
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Churg-Strauss syndrome, cholesterol emboli and NSAIDs. 
Not to overdo the obscure, I also attended lectures on 
lupus nephritis and the management of anti-phospholipid 
antibody syndrome. Th  e lupus session was especially 
popular and completely ﬁ  lled a cavernous hall. To hear 
the talks, I had to sit on the ﬂ  oor in one of the spacious 
lobbies, watching on a big screen TV that glowed brightly 
while the voice of a disembodied lecturer emanated 
scratchily from a sound system. Bottom line. When it 
comes to lupus, hard data are still lacking and people do 
many diﬀ   erent things when confronted with ominous 
rises in the creatinine or the urinary protein. Whether 
lupus will ever have a class IA study for evidence-based 
practice remains to be seen.
Another interesting session that I attended concerned 
muscle disease. While inﬂ  ammatory myopathy is relatively 
rare, concerns about muscle disease are skyrocketing 
related primarily to the widespread use of statins, which 
can bedevil the musculature in a variety of ways. 
Something like 10% of the adult population is taking a 
statin and, as the goal for cholesterol control becomes 
more ambitious, that number can only increase. On the 
radio the other day, I heard a story about cholesterol 
screening for children perhaps triggered by fears of what 
a diet of Big Macs and Whoppers can do. While many 
children will outgrow their elevated cholesterol levels, 
some public health advocates are suggesting statin 
treatment to get a jump on the accelerated atherosclerosis 
that bad lipids can promote. I can see the new happy 
meal: a cheese burger and a side of Lipitor.
While myalgias and cramps are frequent among statin 
users, some patients may develop an inﬂ  ammatory myo-
pathy or inclusion body myositis. Given the frequency of 
statin use, such occurrence may coincidence. Some 
patients, however, present with a newly recognized form 
of myopathy that appears to be genuinely associated with 
statin use and has a fascinating serological proﬁ  le that 
may provide a clue to etiology. Th  us, as described in a 
lecture from Dr Lisa Christopher-Stine from Johns 
Hopkins, statin users are prone to immune-mediated 
necrotizing myopathy (IMMS) that has a distinct set of 
clinical and histopathological ﬁ  ndings.  Th  is condition 
presents with widespread muscle pain and weakness, 
with biopsies showing evidence of myocyte necrosis.
Intriguingly, patients with IMMS express antibodies to 
the target of statin action, the enzyme 3-hydroxy-3-
methyl  glutaryl coenzyme A reductase (HMGCR). Th  is 
serological feature was deﬁ  ned originally by Western blots 
showing antibodies to proteins with molecular weights of 
100 kDa and 200 kDa; molecular techniques established 
the identity of the 100  kDa protein as HMGCR; the 
200  kDa band may result from a dimer or associated 
protein. Th  e link between antibodies to HMGCR and 
statin use suggests a scenario in which statin use decreases 
cholesterol levels, which in turn induces HMGCR 
production. Th  is up-regulation some  how may increase 
immunogenicity and drive the produc  tion of 
autoantibodies that may damage myocytes. Further  more, 
since regenerating muscle can also show HMGCR up-
regulation, a repair response to an initial injury may 
exacerbate autoimmunity, fueling the ﬁ  re with an ever 
increasing supply of autoantigen to stimulate pathogenic 
B and T cell responses.
Th  is model, while attractive and consistent with the 
data, may be insuﬃ     cient to explain an anti-HMGCR 
response since it suggests that the immune system is 
exquisitely sensitive to even small changes in the expres-
sion levels of protein. Other mechanisms may therefore 
be at play. Th   us, binding of a statin to the enzyme could 
create structural change that alters the enzyme’s 
conformation or intracellular metabolism to promote 
autoimmunization. Perhaps muscle has an unusual 
sensitivity to the eﬀ  ects of cholesterol and is predisposed 
to injury as the cholesterol levels drop.
Th   e single session on muscle disease had an abundance 
of food for thought. Indeed, it was a veritable banquet or 
smorgasbord with a profusion of tasty dishes for the 
intellect. Dr Dana Ascherman from the University of 
Miami reviewed potential biomarkers for myositis, dis-
cuss  ing both autoantibodies and markers of immune cell 
dysfunction present in patients with myositis. Th  ese 
muscle-speciﬁ  c antibodies have curious clinical associa-
tions, such as interstitial lung disease, skin ﬁ  ndings and 
vasculitis, with their origin reﬂ  ecting perturbations of the 
innate immune systems that may involve molecules like 
MDA5 (melanoma diﬀ   erentiation gene 5), a target of 
auto  reactity. MDA5 is a cytoplasmic sensor for RNA that 
may be key for the innate immune response to viral 
infection. Could each of these muscle-speciﬁ  c antibodies 
result from some type of environmental insult just as 
anti-HMGCR results from statin exposure?
Th   e implications of these ﬁ  ndings are wide ranging and 
extend from public health to detailed cell and molecular 
biology. On the clinical side are questions like the follow-
ing: is IMMS the tip of the iceberg of statin-induced 
muscle disease - the canary in the mine shaft - that 
should suggest caution in the extent of their use? Should 
patients be screened for the antibodies as a strategy to 
reduce the likelihood of IMMS? How can environmental 
triggers for autoimmunity be found if the risk is so low? 
Th   en there is the question of how statins, a class of agent 
with potential immunosuppressive activity, including 
modulation of T regulatory cells, promote auto  immunity 
at the same time as they dampen other responses.
I was surprisingly attentive at the meeting. I also 
learned about the role of β-catenin in the pathogenesis of 
scleroderma, the treatment of erythema nodosum and 
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ﬁ  rst person who ever stayed at the Palmer House. Th  at 
piece of information was provided by the computer 
screen in the elevator in my hotel. In Chicago, new know-
ledge was everywhere and not just at the convention 
center.
For those of you curious about the ﬁ  rst  animal 
purchased for the zoo or the amusement park ride that 
originated in Chicago, I suggest you do what my fellows 
do when I ask them the diﬀ  erential of hypereosinophilia. 
Th  ey look on Google. While, in medicine, we call this 
approach practice-based learning, the rest of the world 
calls it surﬁ  ng the web. Go for it. Surf’s up and see you at 
the 2012 ACR meeting in Washington.
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